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INTRODUCTION: Type-1 diabetes mellitus is 
defined by the inability to control systemic glucose 
levels, due to an autoimmune destruction of the 
insulin-producing β-cells. Treatment involves 
routine glucose monitoring and insulin infusion. 
However, some patients with hypoglycaemia 
unawareness may require pancreas or islet 
transplantation [1]. Islet transplantation is a 
minimally invasive 'micro-tissue' therapy aimed at 
reducing hyperglycaemia and eliminating severe 
hypoglycaemia. This is achieved by infusing islets 
of Langerhans into the portal vein; where they 
engraft in the liver. Major limitations of islet 
transplantation include the need for life-long 
immunosuppression and a high tissue demand [2]. 
This work aims to overcome these restrictions and 
improve engraftment by applying 3D bioprinting 
to standardise islet size and ECM composition 
with the goal to reduce tissue loss immediately 
post transplantation and improve engraftment. A 
tri-component ‘bioink’ hydrogel was developed 
and investigated using collagen, alginate and fibrin 
(CAF), at three collagen concentrations (0.5%, 1% 
and 2.5%), for β-cell replacement therapy to treat 
type-1 diabetes. 
METHODS: CAF hydrogels were produced +/- 
MIN6 β-cells. Morphology was characterised 
using SEM and TEM, while chemical composition 
was evaluated using XRD and FTIR. Mechanical 
properties, viscosity and biodegradation of the 
hydrogel material was also analysed. CAF 
hydrogels seeded with MIN6 β-cells were cultured 
for 7 days, to assess biocompatibility. Micro-
tissues <150 µm were manufactured using an 
nScrypt 3Dn printer and evaluated for viability, 
metabolic activity, and functionality via 
immunostaining for insulin and E-cadherin.  
RESULTS: CAF hydrogels with 0.5%, 1% and 
2.5% collagen demonstrated pore size in the 40-
200 μm range (Fig. 1A). 0.5% and 1% CAF 
hydrogels had highly inter-connected porosity, 
which was not present in 2.5% gels. TEM showed 
collagen fibre formation in hydrogels made with 1 
% collagen, but not in 0.5 and 2.5% gels (Fig. 1B). 
Rheological testing demonstrated that all CAF 
hydrogels had a G’ modulus of ~1000 Pa, similar 
to human pancreatic tissue [3]. 1 and 2.5% CAF 
hydrogels were stable for >15 days of 
biodegradation, while 0.5% hydrogels 
disintegrated after 5 days. Biocompatibility 
assessed by cell viability and metabolic activity 
was inversely proportional to collagen 
concentration, with the best results found for 0.5% 
collagen. Furthermore, bioink extrusion became 
more difficult as collagen concentration increased 
and 2.5% CAF hydrogels could not be accurately 
extruded. Insulin and E-cadherin immunostaining 
demonstrated similar functionality of MIN6 β-cells 
before and after bioprinting. 
 
Fig. 1: SEM (A) of hydrogel architecture and TEM 
(B) of collagen fibre formation (indicated by 
arrow), in CAF hydrogels made with 1% collagen.  
DISCUSSION & CONCLUSIONS: A novel collagen, 
fibrin and alginate hydrogel (CAF) was developed for 
use as a bioink substrate in the manufacture of islet 
micro-tissues. A general enhancement in mechanical 
properties, porosity and resistance to biodegradation 
was observed with increasing collagen content. This was 
offset by reduced biocompatibility and an increased 
difficulty to extrude the bioinks, which may make 
printing of CAF hydrogels impossible.  7 day culture of 
micro-tissues highlighted the influence of hydrogel 
structure and composition on cell compatibility in 3D – 
demonstrating the necessity for appropriate bioink 
formulation as a substitute for native ECM in 
manufactured micro-tissues. 
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